Phase I study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+ advanced solid tumors

Kadcyla (ado-trastuzumab emtansine) - Roche

ADC2122 - ZovaBio, Adcoris

Perjeta (pertuzumab) - Roche

F. Lin1; Y. Huang2; Y. Lu2; X. Rao3; F. Wang2; Y. Huang4; X. Huang5

Jul 27, 2023